| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/14/2001 | WO2001041745A1 Anti pruritic patch |
| 06/14/2001 | WO2001041744A1 Chronotherapeutic diltiazem formulations and the administration thereof |
| 06/14/2001 | WO2001041743A1 New (aminopropyl)methylphosphinic acids |
| 06/14/2001 | WO2001041742A2 Antiviral medication |
| 06/14/2001 | WO2001041741A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 06/14/2001 | WO2001041740A2 Reconstitution of purified membrane proteins into preformed liposomes |
| 06/14/2001 | WO2001041739A2 Liposomes |
| 06/14/2001 | WO2001041738A2 Lipid carrier compositions with protected surface reactive functions |
| 06/14/2001 | WO2001041737A2 Solid oral dosage form |
| 06/14/2001 | WO2001041736A2 Microchip devices for delivery of molecules and methods of fabrication thereof |
| 06/14/2001 | WO2001041735A2 Thermosensitive biodegradable hydrogels based on low molecular weight pluronics |
| 06/14/2001 | WO2001041734A2 Stable galenic preparations comprising a benzimidazol and method for the production thereof |
| 06/14/2001 | WO2001041733A2 Compressed tablet composition comprising a nsaid |
| 06/14/2001 | WO2001041732A1 Compositions and methods for intranasal delivery of active agents to the brain |
| 06/14/2001 | WO2001041706A2 Lipid nanotubules for topical delivery |
| 06/14/2001 | WO2001041702A2 Zinc thiosalicylate, dermatological compositions containing same, in particular in the form of a self-adhesive device and method for preparing same |
| 06/14/2001 | WO2001041550A2 Topical anesthetic formulation |
| 06/14/2001 | WO2001041536A2 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001028552A3 Antimicrobial compositions comprising pyroglutamic acid and optionally metal salts |
| 06/14/2001 | WO2001024762A3 Method for improving uv radiation stability of photosensitive sunscreen filters |
| 06/14/2001 | WO2001008632A3 Colloidal composition for esthetic correction |
| 06/14/2001 | WO2000078358A3 Hyaluronic acid microspheres for sustained gene transfer |
| 06/14/2001 | WO1998033528A9 Induction of b cell tolerance |
| 06/14/2001 | US20010003753 Methods for treatment of inflammatory diseases |
| 06/14/2001 | US20010003742 Antilipemic formulation |
| 06/14/2001 | US20010003739 Systemic administration of a therapeutic preparation |
| 06/14/2001 | US20010003619 Comprising an effective proportion of highly crosslinked starch particles with limited swelling, enclosed in a matrix of pregelatinised starch |
| 06/14/2001 | US20010003590 Process for manufacturing tablets for the sustained release of active principle(s) |
| 06/14/2001 | US20010003589 Pharmaceutical compositions of macrolides or cyclosporine with a polyethoxylated saturated hydroxy-fatty acid |
| 06/14/2001 | US20010003588 Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride |
| 06/14/2001 | US20010003580 Dissolving a lipid blend in a nonaqueous solvent and adding it to water or an aqueous solution of brine and/or glycerin and/or solvent; uniform particle size; ultrasound contrast agents |
| 06/14/2001 | CA2394060A1 Transmucosal administration of phosphodiesterase inhibitor for the treatment of erectile dysfunction |
| 06/14/2001 | CA2393748A1 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 06/14/2001 | CA2393737A1 Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption |
| 06/14/2001 | CA2393730A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 06/14/2001 | CA2393662A1 Inducing cellular immune responses to p53 using peptide and nucleic acid compositions |
| 06/14/2001 | CA2393601A1 Antiviral medication |
| 06/14/2001 | CA2393595A1 Lipid carrier compositions with protected surface reactive functions |
| 06/14/2001 | CA2393588A1 Solid oral dosage form |
| 06/14/2001 | CA2393526A1 Nucleic acid delivery system |
| 06/14/2001 | CA2393510A1 New (aminopropyl)methylphosphinic acids |
| 06/14/2001 | CA2392764A1 Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions |
| 06/14/2001 | CA2389013A1 Compositions including ether-capped poly(oxyalkylated) alcohol wetting agents |
| 06/14/2001 | CA2388828A1 Topical anesthetic formulation |
| 06/14/2001 | CA2362815A1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | CA2362675A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | CA2361563A1 Use of polyacrylamide gel for forming a connective-tissue capsule in a mammal for cultivating allogenic or xenogenic cells |
| 06/13/2001 | EP1106646A1 Excipient and disintegrant composition, process for obtaining the same and its use |
| 06/13/2001 | EP1106599A1 Chromium l-threonate, process for preparation of the same and their use |
| 06/13/2001 | EP1106177A1 Tumor tissue accumulation enhancers for drugs |
| 06/13/2001 | EP1106174A1 Compositions containing fat-soluble vitamins |
| 06/13/2001 | EP1106149A2 Wound protective material |
| 06/13/2001 | EP1106081A1 Stable, spray-dried composition in a carbohydrate substrate and process for obtaining said composition |
| 06/13/2001 | EP1106068A2 Process for preparing an emulsifier-containing powder |
| 06/13/2001 | EP1105459A1 Transgenic nonhuman mammal and uses thereof to identify compounds useful for improving long-term memory |
| 06/13/2001 | EP1105420A1 Cyclic prosaposin-derived peptides and uses thereof |
| 06/13/2001 | EP1105399A1 Carboxylated phosphatidic acid esters |
| 06/13/2001 | EP1105263A1 Method for producing adhesive blanks from an endless band and blanks obtained according to said method |
| 06/13/2001 | EP1105144A1 Composition and method for eliminating undigested fat and reducing cholesterol in the human body |
| 06/13/2001 | EP1105141A2 Phosphatidylcholine as a medicament for the protection of mucosa |
| 06/13/2001 | EP1105139A1 Ophthalmic solution with tetracycline for topical treatment of dry eye disease |
| 06/13/2001 | EP1105123A1 Pharmaceutical compositions containing lipase inhibitors and chitosan |
| 06/13/2001 | EP1105122A1 Pharmaceutical compositions containing lipase inhibitors |
| 06/13/2001 | EP1105114A1 Nimesulide containiing topical pharmaceutical compositions |
| 06/13/2001 | EP1105111A1 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
| 06/13/2001 | EP1105110A1 Spray on bandage and drug delivery system |
| 06/13/2001 | EP1105109A1 Injectable formulations of nanoparticulate naproxen |
| 06/13/2001 | EP1105108A1 Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
| 06/13/2001 | EP1105107A1 Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| 06/13/2001 | EP1105105A1 Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles |
| 06/13/2001 | EP1105104A1 Extended release buccal bioadhesive tablet |
| 06/13/2001 | EP1105103A2 Exactly divisible tablet |
| 06/13/2001 | EP1105102A1 Pharmaceutical composition for injection based on a pharmaceutically acceptable clopidogrel or ticlopidin salt |
| 06/13/2001 | EP1105101A2 Compositions and methods for treating intracellular infections |
| 06/13/2001 | EP1105100A1 Alginate capsules for use in the treatment of brain tumour |
| 06/13/2001 | EP1105099A2 Fish gelatinous composition for use as an ingredient in tablets |
| 06/13/2001 | EP1105098A1 Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient |
| 06/13/2001 | EP1105097A2 Targeted vesicular constructs for cytoprotection and treatment of h.pylori infections |
| 06/13/2001 | EP1105096A1 Injectable aqueous dispersions of propofol |
| 06/13/2001 | EP1105095A2 Biodegradable microparticles gel composition |
| 06/13/2001 | EP1105094A1 Methods for forming regional tissue adherent barriers and drug delivery systems |
| 06/13/2001 | EP1105089A1 Gel-based cosmetic composition |
| 06/13/2001 | EP1007021B1 Transdermal, oral and intravenous preparations of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
| 06/13/2001 | EP0988007A4 Intravaginal drug delivery system and discharge collection device |
| 06/13/2001 | EP0967975B1 Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid |
| 06/13/2001 | EP0877598B1 Anthelmintic paste |
| 06/13/2001 | EP0825876B1 Composition and method of enhancing electrotransport agent delivery |
| 06/13/2001 | EP0814778B1 Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof |
| 06/13/2001 | EP0797432B1 Oil-in-water emulsions |
| 06/13/2001 | EP0789562B1 Sustained release caffeine formulation |
| 06/13/2001 | EP0743851B1 Lipophilic carrier preparations |
| 06/13/2001 | EP0710103B1 Pharmaceutical compositions for hardly soluble active substances |
| 06/13/2001 | EP0686034B1 Bisacodyl dosage form |
| 06/13/2001 | EP0678019B1 Enhanced solubility pharmaceutical solutions |
| 06/13/2001 | EP0651765B1 Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis |
| 06/13/2001 | EP0635040B1 Crosslinked biocompatible encapsulation compositions and methods |
| 06/13/2001 | DE19957762A1 Vessel-like particles comprising encapsulated cells which provide material exchange with their surroundings are useful as a substitute for feeder cells in animal cell cultures |
| 06/13/2001 | DE19957371A1 Mitomycin C-Lösung Mitomycin C solution |
| 06/13/2001 | CN1299291A Implantable particles for tissue bulking and the treatment of gastroesophageal reflux diosease |
| 06/13/2001 | CN1299290A High viscosity liquid controlled delivery system as a Device |